Modulating regulatory T cell function in JIA with Vitamin B3 (nicotinamide) treatment - B-Vit in JIA

MC Utrecht0 个研究点开始时间: 2017年9月14日最近更新: 2017年10月2日

适应症

试验速览

暂无简介。

•- Patients with a diagnosis of oligo-articular or poly-articular JIA with active disease in 1 or multiple joints and an indication for intra-articular corticosteroid injection.
•- Age between 4 to 18 years
•- At the moment of inclusion, not on non-biological DMARD (Methotrexate) treatment or on stable DMARD treatment (at least 3 months of stable Methotrexate use).
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 30
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- no informed consent possible by patient/parents or caregivers
•- participation in other interventional trials
•- Treatment with biological DMARD
•- Recently started treatment with non-biological DMARD (Methotrexate). Defined as treatment for a period less than 3 months.
•- Use of systemic corticosteroids
•- Relevant co morbidity: raised liver enzymes (>2x upper limit) and/or evidence of bone marrow failure (pancytopenia based upon full blood count).

发起方

MC Utrecht